关注
Inge Govaerts
Inge Govaerts
postdoctoral researcher Northwestern university
在 northwestern.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
S Degryse, CE De Bock, S Demeyer, I Govaerts, S Bornschein, D Verbeke, ...
Leukemia 32 (3), 788-800, 2018
852018
Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia
L Albertí-Servera, S Demeyer, I Govaerts, T Swings, J De Bie, O Gielen, ...
Blood, The Journal of the American Society of Hematology 137 (6), 801-811, 2021
552021
JAK/STAT pathway mutations in T-ALL, including the STAT5B N642H mutation, are sensitive to JAK1/JAK3 inhibitors
I Govaerts, K Jacobs, R Vandepoel, J Cools
HemaSphere 3 (6), e313, 2019
182019
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia
I Govaerts, C Prieto, C Vandersmissen, O Gielen, K Jacobs, S Provost, ...
Journal of Hematology & Oncology 14 (1), 97, 2021
112021
Identification of novel targets for treatment in T-cell acute lymphoblastic leukemia
I Govaerts
2023
P348: MRK-560 AND DEXAMETHASONE ARE SYNERGISTIC IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
C Vandersmissen, CP Fernàndez, O Gielen, K Jacobs, I Govaerts, ...
HemaSphere 6, 248-249, 2022
2022
Evolution of Clinically Relevant Subclones during Chemotherapy Treatment of ALL As Determined By Single-Cell DNA and RNA Sequencing
LA Servera, S Demeyer, I Govaerts, O Gielen, H Segers, A Uyttebroeck, ...
Blood 134, 2749, 2019
2019
PF159 COMBINATION OF SELECTIVE GAMMA-SECRETASE INHIBITOR MRK-560 WITH OTHER TARGETED THERAPY IS AN EFFECTIVE AND SAFE TREATMENT FOR T-ALL
I Govaerts, O Gielen, R Habets, C de Bock, K De Keersmaecker, H Segers, ...
HemaSphere 3 (S1), 31, 2019
2019
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
S Degryse, CE de Bock, S Demeyer, I Govaerts, S Bornschein, D Verbeke, ...
Leukemia 32 (12), 2731, 2018
2018
系统目前无法执行此操作,请稍后再试。
文章 1–9